Filtered By:
Source: Heart International
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 160 results found since Jan 2013.
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
Rapid Atrial Fibrillation in the Emergency Department
Heart Int. 2022 Jun 30;16(1):12-19. doi: 10.17925/HI.2022.16.1.12. eCollection 2022.ABSTRACTAtrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (Europea...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Mochamad Yusuf Alsagaff Hendri Susilo Christian Pramudia Dafsah Arifa Juzar Muhammad Rafdi Amadis Rerdin Julario Sunu Budhi Raharjo Budi Baktijasa Dharmadjati Terrence Timothy Evan Lusida Yusuf Azmi Pieter Afm Doevendans Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
Rapid Atrial Fibrillation in the Emergency Department
Heart Int. 2022 Jun 30;16(1):12-19. doi: 10.17925/HI.2022.16.1.12. eCollection 2022.ABSTRACTAtrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (Europea...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Mochamad Yusuf Alsagaff Hendri Susilo Christian Pramudia Dafsah Arifa Juzar Muhammad Rafdi Amadis Rerdin Julario Sunu Budhi Raharjo Budi Baktijasa Dharmadjati Terrence Timothy Evan Lusida Yusuf Azmi Pieter Afm Doevendans Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
Rapid Atrial Fibrillation in the Emergency Department
Heart Int. 2022 Jun 30;16(1):12-19. doi: 10.17925/HI.2022.16.1.12. eCollection 2022.ABSTRACTAtrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (Europea...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Mochamad Yusuf Alsagaff Hendri Susilo Christian Pramudia Dafsah Arifa Juzar Muhammad Rafdi Amadis Rerdin Julario Sunu Budhi Raharjo Budi Baktijasa Dharmadjati Terrence Timothy Evan Lusida Yusuf Azmi Pieter Afm Doevendans Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
Rapid Atrial Fibrillation in the Emergency Department
Heart Int. 2022 Jun 30;16(1):12-19. doi: 10.17925/HI.2022.16.1.12. eCollection 2022.ABSTRACTAtrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (Europea...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Mochamad Yusuf Alsagaff Hendri Susilo Christian Pramudia Dafsah Arifa Juzar Muhammad Rafdi Amadis Rerdin Julario Sunu Budhi Raharjo Budi Baktijasa Dharmadjati Terrence Timothy Evan Lusida Yusuf Azmi Pieter Afm Doevendans Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
Rapid Atrial Fibrillation in the Emergency Department
Heart Int. 2022 Jun 30;16(1):12-19. doi: 10.17925/HI.2022.16.1.12. eCollection 2022.ABSTRACTAtrial fibrillation (AF) is the most common rhythm disorder seen in doctors' offices and emergency departments (EDs). In both settings, an AF holistic pathway including anticoagulation or stroke avoidance, better symptom management, and cardiovascular and comorbidity optimization should be followed. However, other considerations need to be assessed in the ED, such as haemodynamic instability, the onset of AF, the presence of acute heart failure and pre-excitation. Although the Advanced Cardiovascular Life Support guidelines (Europea...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Mochamad Yusuf Alsagaff Hendri Susilo Christian Pramudia Dafsah Arifa Juzar Muhammad Rafdi Amadis Rerdin Julario Sunu Budhi Raharjo Budi Baktijasa Dharmadjati Terrence Timothy Evan Lusida Yusuf Azmi Pieter Afm Doevendans Source Type: research
Andexanet Alfa and its Clinical Application
Heart Int. 2020 Jun 19;14(1):20-23. doi: 10.17925/HI.2020.14.1.20. eCollection 2020.ABSTRACTFactor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Rece...
Source: Heart International - October 24, 2022 Category: Cardiology Authors: Fauve A Noordergraaf Marco Alings Source Type: research
